CMC-only CRL clears the clinical bar but leaves approval timing uncertain; resubmission success determines whether the trimodal dexmethylphenidate ADHD bet pays off

Cingulate is a clinical-stage biotech company developing a targeted ADHD medication that is not yet approved; the treatment cleared Phase 3 testing but received a manufacturing-focused rejection letter, leaving approval contingent on addressing FDA manufacturing concerns.

CTx-1301, a trimodal precision-release dexmethylphenidate formulation for ADHD, cleared Phase 3 and received a CRL citing only manufacturing and CMC deficiencies, with no clinical safety or efficacy concerns. The thesis resolves on whether FDA accepts the CMC resubmission and grants approval, with runway extending to mid-2027 providing a narrow but real window. The primary risk is execution: CMC resubmissions can surface new FDA questions, and dilutive equity financing has already pressured the share structure ahead of any commercial return.